Lisa Anson, chief executive of (), caught up with Proactive's Andrew Scott to discuss the restart of a Phase I/IIa clinical trial of its lead cancer drug in the first half of next year.
The announcement follows what's been described as a “positive” meeting with the Medicines and Healthcare products Regulatory Agency, the drugs watchdog.
Anson says as well as a newly-proposed lower starting dose of RXC004, there will be a revised study protocol, including enhanced safety monitoring.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
